Silva, 36 patient nitazoxanide early treatment RCT: 26% improved viral clearance [p=0.36] https://c19p.org/silva
copied to clipboard
Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study
et al., medRxiv, doi:10.1101/2021.03.03.21252509 (Preprint), NCT04463264 (history)
Small RCT with 23 nitazoxanide and 13 control patients showing significantly more patients achieved over 35% reduction in viral load from baseline. NCT04463264 (history).
|
relative mean improvement in Ct, 26.5% better, RR 0.74, p = 0.36, treatment 23, control 13.
|
|
risk of viral load reduction < 35% at day 7, 38.3% lower, RR 0.62, p = 0.08, treatment 12 of 23 (52.2%), control 11 of 13 (84.6%), NNT 3.1.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Silva et al., 5 Mar 2021, Single Blind Randomized Controlled Trial, Argentina, preprint, 11 authors, trial NCT04463264 (history).
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.